Moderna, Inc. (MRNA): A Bull Case Theory [Yahoo! Finance]
Moderna, Inc. (MRNA)
Last moderna, inc. earnings: 2/26 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
marinabio.com/investor-relations
Company Research
Source: Yahoo! Finance
In this article, we will summarize the bulls' thesis on MRNA. Moderna, Inc.'s share was trading at $29.92 as of December 15th. MRNA's trailing P/E was 7.06 according to Yahoo Finance. Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. MRNA's strategy from 2025–2030 emphasizes capital efficiency and asset optimization as the company transitions from pandemic-driven expansion to disciplined operations. With manufacturing largely built out, annual CapEx will normalize at $250–300 million, targeting automation, predictive maintenance, and modular production. Facility utilization is expected to rise to 70–80% by 2026–2027, driving gross margins toward 45–50% by 2028 and boosting free cash flow. Geographic diversification through smaller hubs in Europe and Asia aims to serve regional markets efficiently and mitigate supply chain risks, while net PP&E remains flat at $2.1–2.3 billion, reflecting a shift from idle ca
Show less
Read more
Impact Snapshot
Event Time:
MRNA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRNA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRNA alerts
High impacting Moderna, Inc. news events
Weekly update
A roundup of the hottest topics
MRNA
News
- Defiance Launches MRNX: The First Daily 2X Long ETF for Moderna, Inc.GlobeNewswire
- Moderna: Analyzing The January Rally And The Road Ahead (Rating Upgrade) [Seeking Alpha]Seeking Alpha
- Moderna (NASDAQ:MRNA) had its "underperform" rating reaffirmed by analysts at Leerink Partners.MarketBeat
- Moderna (NASDAQ:MRNA) had its "hold" rating reaffirmed by analysts at TD Cowen.MarketBeat
- Moderna (NASDAQ:MRNA) is now covered by analysts at Barclays PLC. They set an "equal weight" rating and a $25.00 price target on the stock.MarketBeat
MRNA
Earnings
- 11/6/25 - Beat
MRNA
Sec Filings
- 2/9/26 - Form SCHEDULE
- 2/6/26 - Form SCHEDULE
- 2/5/26 - Form SCHEDULE
- MRNA's page on the SEC website